Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?

In this webinar, our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?

Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to:

- Overall and rare disease patient populations
- Access inequalities
- Time to diagnosis
- Access to innovation timelines
- Healthcare funding
- Health technology assessment frameworks

Robert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.

Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.

Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.

Learn more at and request a copy of the webinar slides at: [ Ссылка ]

Discover how Mtech Access can support you with market access, pricing and reimbursement for rare disease treatments at: [ Ссылка ]

Jump to:

00:00 - Welcome and introductions
02:04 - MENA healthcare environment for orphan medicines
03:30 - Nordics healthcare environment for orphan medicines
05:24 - Patient demographics in Nordics
07:21 - Patient demographics in the MENA region
08:19 - Rare disease populations in MENA and Nordic regions
10:42 - Challenges in accessing healthcare in the MENA region
12:35 - Access to healthcare in the Nordics
15:29 - Reducing health inequalities for rare diseases in the Nordic regions
16:34 - Healthcare funding across the MENA region for rare disease patients
18:49 - Healthcare funding across the Nordics for rare disease patients
23:48 - Challenges in reaching a rare disease diagnosis
29:40 - Access to rare disease medicines and innovative treatments
35:03 - Assessment frameworks and pricing strategies for rare disease treatments / orphan drugs in the MENA region
41:23 - Assessment frameworks and pricing strategies for rare disease treatments / orphan drugs in the MENA region
56:34 - Quick summary and take home messages

свернуть